Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Lee Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSIR-IICT Licenses Process Knowhow for Synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Marc Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covid-19 Patients with Colchicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by CSIR-Indian Institute of Chemical Technology

    Menu

    CSIR-Indian Institute of Chemical Technology

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CSIR-Indian Institute of Chemical Technology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke

              Details:

              The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.

              Lead Product(s): S007-867

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: S007-867

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Marc Laboratories

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CSIR-Indian Institute of Chemical Technology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covid-19 Patients with Colchicine

              Details:

              CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.

              Lead Product(s): Colchicine,Niclosamide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: LAXAI Life Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CSIR-Indian Institute of Chemical Technology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CSIR-IICT Licenses Process Knowhow for Synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd.

              Details:

              Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufacture the drug.

              Lead Product(s): 2-Deoxy-D-Glucose

              Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lee Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CSIR-Indian Institute of Chemical Technology

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins

              Details:

              The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.

              Lead Product(s): Niclosamide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: LAXAI Life Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY